Drug Abuse
Drug abuse and its consequences represent a major public health challenge documented across all demographic groups and geographic regions. This harm reduction portal synthesises evidence-based guidance from public health organisations, peer-reviewed medical literature, and harm-reduction charities to help individuals who use substances make safer decisions. All guidance on this page derives from publicly available medical and public health sources. This content does not encourage drug use; it documents safety practices to reduce the risk of death and serious injury among people who use drugs.
Harm reduction is a public health approach that acknowledges the reality of drug use and prioritises reducing its negative consequences over demanding abstinence. The approach is endorsed by the World Health Organization (who.int), the European Monitoring Centre for Drugs and Drug Addiction (emcdda.europa.eu), and national health authorities in Canada, the United Kingdom, Portugal, and dozens of other jurisdictions.
Overdose Recognition and Emergency Response for Drugs First Aid
Opioid overdose is the leading cause of drug-related death in most high-income countries. It is recognisable by three signs documented as the "opioid overdose triad" in emergency medicine literature: unconsciousness or extreme drowsiness; slow, shallow, or absent breathing; and pinpoint (constricted) pupils. If any of these signs are present in a person who has used opioids, treat it as a medical emergency.
Naloxone (brand name Narcan) is an opioid antagonist that reverses opioid overdose within minutes of administration. It is available without prescription in many jurisdictions in intranasal, intramuscular, and sublingual formulations. Naloxone is stocked by most pharmacies in Canada, the United Kingdom, the United States (in most states), and across the EU. The NEXT Distro harm-reduction platform (nextdistro.org) provides US-specific naloxone access information; BTNX (btnx.com) publishes the product information for Narcan nasal spray.
Emergency response steps for suspected opioid overdose, per EMCDDA and WHO published guidelines: (1) Call emergency services immediately. (2) Administer naloxone if available. (3) Place the person in the recovery position if breathing. (4) If not breathing, begin rescue breathing. (5) Administer a second naloxone dose after 2–3 minutes if no response. (6) Stay with the person until emergency services arrive — naloxone's effect lasts 30–90 minutes and a second overdose can occur as it wears off.
Stimulant overdose (cocaine, methamphetamine, MDMA, amphetamine) presents differently from opioid overdose: the person may be conscious, agitated, and experiencing a racing heart, dangerously elevated body temperature, chest pain, or seizures. Stimulant overdose is a medical emergency requiring immediate emergency-service contact. There is no reversal agent equivalent to naloxone for stimulants. Keep the person cool, calm, and still; do not restrain forcibly; do not give food or water if a seizure is possible.
Drug Consumption Safety by Substance Category
The following safety guidance is derived from EMCDDA Drug Profiles, WHO Essential Medicines documentation, and published harm-reduction organisation resources.
Opioids (heroin, fentanyl, oxycodone, tramadol): Never use alone — have someone present who can call emergency services. Test for fentanyl using fentanyl test strips (BTNX FTS) before consuming any unknown opioid. Start with a small test dose if source or potency is unknown. Do not mix with alcohol, benzodiazepines, or other CNS depressants — this combination is responsible for a majority of opioid overdose deaths documented in coroner data. The EMCDDA publishes annual drug-related death statistics and fentanyl prevalence data at emcdda.europa.eu.
MDMA / Ecstasy: The primary acute risks documented in clinical literature are hyperthermia (dangerously elevated body temperature), hyponatraemia (dangerous dilution of blood sodium from excessive water intake), and serotonin syndrome when combined with other serotonergic drugs. Harm-reduction guidance from The Loop (wearetheloop.org): dose below 1.5 mg/kg body weight; take breaks from physical exertion; drink no more than 500 ml of water per hour; do not combine with SSRIs, MAOIs, tramadol, or other serotonergic substances. Drug checking services can identify adulterants including methamphetamine and bath salts that have been found in MDMA tablets in European market monitoring.
Benzodiazepines: Physical dependence develops with regular use within 2–4 weeks at therapeutic doses. Abrupt cessation after dependence can cause life-threatening withdrawal seizures — do not stop benzodiazepines abruptly after extended use without medical guidance. The Ashton Manual (benzo.org.uk/manual), authored by Professor Heather Ashton, is the most widely referenced clinical guide for benzodiazepine tapering and is endorsed by numerous harm-reduction and medical organisations.
Cannabis: High-potency THC products (particularly concentrates above 40% THC) have been associated with cannabis hyperemesis syndrome and acute psychosis in clinical literature, particularly in individuals with personal or family history of psychotic disorders. The EMCDDA TEDI drug monitoring programme tracks THC potency trends across European markets. Harm-reduction guidance: use low-THC or balanced CBD:THC preparations; avoid mixing with tobacco; do not drive or operate machinery; and be aware of the substantially higher potency of edible cannabis products, which have a delayed onset of 30–120 minutes, leading to common dosing errors.
Cocaine: The primary documented cardiovascular risks are vasospasm, arrhythmia, and myocardial infarction, risks that are substantially elevated by concurrent alcohol consumption (which produces cocaethylene, a cardiotoxic metabolite). Cocaine sold on secondary markets is frequently adulterated; drug-checking services documented adulterants including levamisole (immune suppression risk), phenacetin (carcinogenic), and fentanyl (overdose risk). The Loop and WEDINOS in the UK provide drug checking and results publication at wedinos.org.
For drug interaction checks covering all documented major drug combinations, DrugsData (drugsdata.org) and TripSit (tripsit.me/drug-combinations) provide publicly accessible interaction tables based on published clinical and pharmacological literature. The operational security guide addresses digital safety practices relevant to sourcing harm-reduction information privately.
Harm Reduction Portal: Key Resources
The following organisations publish evidence-based harm-reduction resources accessible to the public:
- DanceSafe (dancesafe.org) — drug checking supplies and education for nightlife settings
- The Loop (wearetheloop.org) — UK drug-checking service and MDMA/stimulant harm reduction
- EMCDDA (emcdda.europa.eu) — European drug statistics, drug profiles, and harm-reduction policy
- WHO Drug Dependence (who.int/substance_abuse) — global public health guidance on drug dependence
- TripSit (tripsit.me) — drug combination charts and fact sheets based on clinical literature
- DrugsData (drugsdata.org) — laboratory drug checking results database
- Harm Reduction International (hri.global) — international harm reduction policy and advocacy